HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ezzat, S. Articles by Kovacs, K. Search for Related Content PubMed Articles by Ezzat, S. Articles by Kovacs, K.

In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide

Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995;133:686–90. ISSN 0804–4643

The somatostatin analog, octreotide, is an inhibitor of growth hormone (GH) secretion that has been used to treat patients with GH-producing pituitary tumors. In this study we investigated the in vivo responsiveness to treatment with this analog in patients harboring different morphological types of GH-producing pituitary adenomas. Both GH and insulin-like growth factor I (IGF-I) plasma levels in 30 patients treated with octreotide (300 µg/day) for 4 months preoperatively were compared with those from 30 patients who did not receive treatment preoperatively. Tissue samples were studied using ultrastructural and immunohistochemical techniques. Amongst patients harboring densely granulated (DG) adenomas, mean GH levels were reduced to 32 ± 9% by octreotide, to 30 ± 7% by surgery and to 26 ± 9% of baseline by both interventions. Surgery was equally as effective in lowering GH levels in patients with sparsely granulated (SG) adenomas as it was in those with DG adenomas; in patients with SG adenomas, GH levels were reduced by surgery alone to 37 ± 16% and to 24 ± 15% when performed following octreotide pretreatment. In contrast, treatment with octreotide alone in patients harbouring SG adenomas reduced GH levels to only 70 ± 13% of baseline (p < 0.02 compared to surgery alone, or surgery and octreotide). We conclude that the GH inhibitory effects of octreotide are significantly better in patients harboring DG somatotroph adenomas compared with those harboring SG adenomas.

Shereen Ezzat, University of Toronto-Wellesley Hospital, 160 Wellesley St East, Toronto, Ontario M4Y-1J3, Canada

This article has been cited by other articles:

				S. L. Asa, R. DiGiovanni, J. Jiang, M. L. Ward, K. Loesch, S. Yamada, T. Sano, K. Yoshimoto, S. J. Frank, and S. Ezzat A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors Cancer Res., August 1, 2007; 67(15): 7505 - 7511. [Abstract] [Full Text] [PDF]

				N Y Y Al-Brahim and S L Asa My approach to pathology of the pituitary gland J. Clin. Pathol., December 1, 2006; 59(12): 1245 - 1253. [Abstract] [Full Text] [PDF]

				S. Bhayana, G. L. Booth, S. L. Asa, K. Kovacs, and S. Ezzat The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6290 - 6295. [Abstract] [Full Text] [PDF]

				G M Besser, P Burman, and A F Daly Predictors and rates of treatment-resistant tumor growth in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193. [Abstract] [Full Text] [PDF]

				R Chetty and S L Asa Pancreatic endocrine tumour with cytoplasmic keratin whorls. Is the term "rhabdoid" appropriate? J. Clin. Pathol., October 1, 2004; 57(10): 1106 - 1110. [Abstract] [Full Text] [PDF]

				A. Saveanu, G. Gunz, H. Dufour, P. Caron, F. Fina, L. Ouafik, M. D. Culler, J. P. Moreau, A. Enjalbert, and P. Jaquet BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 140 - 145. [Abstract] [Full Text]

				P. Jaquet, A. Saveanu, G. Gunz, F. Fina, A. J. Zamora, M. Grino, M. D. Culler, J. P. Moreau, A. Enjalbert, and L'H. Ouafik Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral Phenotypes J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 781 - 792. [Abstract] [Full Text]

				S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]